Correlation of tenascin-C degradation fragment with recurrence and/or metastasis in early non-small-cell lung cancer / 中华肿瘤杂志
Chinese Journal of Oncology
;
(12): 518-521, 2007.
Article
Dans Chinois
| WPRIM
| ID: wpr-298561
ABSTRACT
<p><b>OBJECTIVE</b>To study the correlation of tenascin-c (TN-C) degradation with relapse and/or metastasis in stage-I non-small cell lung cancer (NSCLC) in order to search for a potential biomarker for predicting recurrence, and also to investigate the molecular mechanism of TN-C degradation. Methods The fragment of TN-C in 63 surgically treated stage-I NSCLC was detected by Western blotting, and the activity of matrix metalloproteinases (MMPs) was also examined by gelatin zymography.</p><p><b>RESULTS</b>TN-C degradation fragment was positively detected in 12 of 63 patients, and 9 of these 12 patients (75.0%) were found to develope recurrence during follow-up. The recurrence-free survival at 4 years was 28.1% in patients with positive TN-C degradation versus 82.1% in those without (P < 0.001), and which was 76.6% at 10 years in the patients without TN-C degradation. The activity of MMP-2 in the patients with positive TN-C degradation was also found to be significantly higher than that in the patients without (P < 0.001).</p><p><b>CONCLUSION</b>Tenascin-c degradation fragment may be a reliable biomarker for predicting recurrence and/or metastasis in the early NSCLC, and matrix metalloproteinase-2 may be a responsible proteinase for degradation of tenascin-c.</p>
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Anatomopathologie
/
Pneumonectomie
/
Chirurgie générale
/
Tumeurs osseuses
/
Tumeurs du cerveau
/
Marqueurs biologiques tumoraux
/
Études de suivi
/
Carcinome pulmonaire non à petites cellules
/
Ténascine
/
Matrix metalloproteinase 2
Type d'étude:
Étude observationnelle
/
Étude pronostique
Limites du sujet:
Adulte très âgé
/
Aged80
/
Femelle
/
Humains
/
Mâle
langue:
Chinois
Texte intégral:
Chinese Journal of Oncology
Année:
2007
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS